MYGN - Myriad Genetics Inc Stock Price, Fair Value and News

25.30USD+0.69 (+2.80%)Market Closed

Market Summary

USD25.30+0.69

Market Closed

2.80%

MYGN Alerts

Big jump in Earnings (Y/Y)

Losses in recent quarter

MYGN Stock Price

View Fullscreen

MYGN RSI Chart

MYGN Valuation

Market Cap

2.3B

Price/Earnings (Trailing)

-9.76

Price/Sales (Trailing)

2.96

EV/EBITDA

-12.75

Price/Free Cashflow

-23.78

MYGN Price/Sales (Trailing)

MYGN Profitability

Operating Margin

81.10%

EBT Margin

-30.42%

Return on Equity

-30.87%

Return on Assets

-21.13%

Free Cashflow Yield

-4.21%

MYGN Fundamentals

MYGN Revenue

Revenue (TTM)

774.2M

Rev. Growth (Yr)

11.59%

Rev. Growth (Qtr)

2.85%

MYGN Earnings

Earnings (TTM)

-234.6M

Earnings Growth (Yr)

52.47%

Earnings Growth (Qtr)

16.67%

Breaking Down MYGN Revenue

Last 7 days

-0.7%

Last 30 days

35.7%

Last 90 days

8.8%

Trailing 12 Months

34.8%

How does MYGN drawdown profile look like?

MYGN Financial Health

Current Ratio

1.99

Debt/Equity

0.05

Debt/Cashflow

-2.49

MYGN Investor Care

Shares Dilution (1Y)

10.98%

Diluted EPS (TTM)

-2.8

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	774.2M	0	0	0
2023	694.7M	698.9M	734.4M	753.2M
2022	682.4M	672.3M	661.4M	678.4M
2021	566.1M	662.3M	684.4M	690.6M
2020	760.8M	638.6M	597.5M	557.0M
2019	829.6M	851.1M	835.1M	813.4M
2018	749.4M	743.7M	767.2M	796.1M
2017	743.5M	769.9M	769.8M	761.0M
2016	756.6M	740.5M	735.9M	739.3M
2015	721.9M	722.5M	737.2M	746.1M
2014	763.6M	778.2M	744.5M	724.9M
2013	572.0M	613.2M	682.2M	737.1M
2012	470.5M	496.0M	519.0M	545.3M
2011	388.6M	402.1M	420.7M	443.0M
2010	353.6M	362.6M	369.4M	377.1M
2009	0	326.5M	335.6M	344.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Myriad Genetics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 14, 2024	verratti mark	sold (taxes)	-21,035	19.55	-1,076	chief commercial officer
Apr 14, 2024	muzzey dale	sold (taxes)	-18,377	19.55	-940	chief scientific officer
Apr 06, 2024	munk natalie	sold (taxes)	-11,771	20.26	-581	chief accounting officer
Mar 25, 2024	munk natalie	sold (taxes)	-7,978	21.98	-363	chief accounting officer
Mar 24, 2024	diaz paul j	sold (taxes)	-1,019,080	22.24	-45,822	president and ceo
Mar 24, 2024	haas kevin richard	sold (taxes)	-64,273	22.24	-2,890	chief technology officer
Mar 24, 2024	muzzey dale	sold (taxes)	-20,972	22.24	-943	chief scientific officer
Mar 24, 2024	verratti mark	sold (taxes)	-72,168	22.24	-3,245	chief commercial officer
Mar 24, 2024	munk natalie	sold (taxes)	-21,817	22.24	-981	chief accounting officer
Mar 22, 2024	diaz paul j	sold (taxes)	-449,292	22.24	-20,202	president and ceo

Which funds bought or sold MYGN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	Pineridge Advisors LLC	reduced	-77.54	-3,387	1,130	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	added	2.97	242,631	1,892,940	-%
May 16, 2024	COMERICA BANK	reduced	-3.45	119,716	1,705,240	0.01%
May 16, 2024	Tidal Investments LLC	new	-	606,170	606,170	0.01%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-44.61	-460,469	741,638	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	unchanged	-	91.00	895	-%
May 15, 2024	PURA VIDA INVESTMENTS, LLC	reduced	-10.55	-3,463	953,537	0.16%
May 15, 2024	Point72 Asset Management, L.P.	new	-	16,591,100	16,591,100	0.04%
May 15, 2024	D. E. Shaw & Co., Inc.	reduced	-29.71	-7,483,470	26,993,500	0.02%
May 15, 2024	AQR CAPITAL MANAGEMENT LLC	reduced	-37.78	-167,998	379,368	-%

Are Funds Buying or Selling MYGN?

Are funds buying MYGN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MYGN

No. of Funds

Unveiling Myriad Genetics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 01, 2024	integrated core strategies (us) llc	5.0%	4,544,150	SC 13G
Apr 25, 2024	integrated core strategies (us) llc	4.97%	4,493,261	SC 13G
Mar 18, 2024	millennium management llc	4.7%	4,262,021	SC 13G
Feb 14, 2024	camber capital management lp	8.5%	2,013	SC 13G/A
Feb 14, 2024	glenview capital management, llc	5.97%	5,283,982	SC 13G/A
Feb 13, 2024	vanguard group inc	11.12%	9,954,233	SC 13G/A
Feb 08, 2024	wellington management group llp	8.07%	7,219,706	SC 13G/A
Jan 24, 2024	state street corp	5.25%	4,700,631	SC 13G/A
Jan 23, 2024	integrated core strategies (us) llc	4.0%	3,559,497	SC 13G/A
Jan 22, 2024	blackrock inc.	16.6%	14,658,349	SC 13G/A

Recent SEC filings of Myriad Genetics Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	144	Notice of Insider Sale Intent
May 15, 2024	4	Insider Trading
May 15, 2024	4	Insider Trading
May 14, 2024	144	Notice of Insider Sale Intent
May 13, 2024	144	Notice of Insider Sale Intent
May 13, 2024	144	Notice of Insider Sale Intent
May 08, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
May 01, 2024	SC 13G	Major Ownership Report
Apr 25, 2024	SC 13G	Major Ownership Report

Peers (Alternatives to Myriad Genetics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	196.9B	23.7B	11.04%	17.40%	44.73	8.29	-8.94%	-35.91%
A	45.2B	6.7B	14.64%	19.44%	36.57	6.71	-2.81%	-6.58%
IDXX	44.9B	3.7B	13.71%	10.52%	51.83	12.06	8.57%	23.94%
DGX	16.0B	9.3B	13.66%	10.24%	18.95	1.73	-3.29%	6.68%
NTRA	13.1B	1.2B	17.80%	114.36%	-35.76	10.81	39.26%	33.08%
MEDP	12.2B	2.0B	2.71%	87.82%	38.94	6.2	25.57%	21.62%
CRL	11.4B	4.1B	-3.66%	11.24%	26.02	2.78	0.49%	-11.59%
EXAS	9.3B	2.5B	-20.33%	-38.03%	-38.69	3.67	15.21%	53.51%
MID-CAP
GH	3.1B	603.7M	54.73%	-14.09%	-6.73	5.14	25.21%	30.68%
NEOG	2.9B	929.2M	11.70%	-18.80%	1.9K	3.16	28.93%	111.61%
SMALL-CAP
CDNA	808.3M	275.1M	87.44%	103.94%	-4.41	2.94	-13.93%	-126.97%
ACRS	84.8M	31.1M	-3.25%	-85.34%	-1.1	2.73	0.95%	19.75%
AWH	33.0M	9.2M	-24.07%	-37.65%	-2.24	3.6	11.85%	45.80%
APDN	2.5M	5.5M	-62.31%	120.18%	-0.2	0.45	-68.52%	-141.15%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Myriad Genetics Inc News

Latest updates

Myriad Genetics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	2.8%	202,200,000	196,600,000	191,900,000	183,500,000	181,200,000	177,800,000	156,400,000	179,300,000	164,900,000	160,800,000	167,300,000	189,400,000	173,100,000	154,600,000	145,200,000	93,200,000	164,000,000	195,100,000	186,300,000	215,400,000	216,600,000
Costs and Expenses	0.9%	230,100,000	228,000,000	252,000,000	297,200,000	233,400,000	230,000,000	201,400,000	197,100,000	190,500,000	203,900,000	247,200,000	210,200,000	219,800,000	202,800,000	184,800,000	161,500,000	297,700,000	203,900,000	207,200,000	221,000,000	210,700,000
S&GA Expenses	-2.6%	140,600,000	144,400,000	136,100,000	140,700,000	151,700,000	146,500,000	130,500,000	127,100,000	110,600,000	75,600,000	180,600,000	135,200,000	146,400,000	132,800,000	124,100,000	107,400,000	132,900,000	134,300,000	135,500,000	149,800,000	140,600,000
R&D Expenses	18.6%	24,900,000	21,000,000	24,000,000	21,200,000	22,500,000	23,400,000	20,500,000	20,300,000	21,200,000	20,500,000	18,800,000	19,500,000	23,100,000	18,200,000	17,600,000	17,400,000	19,700,000	18,800,000	21,300,000	20,900,000	21,500,000
EBITDA Margin	14.0%	-0.23	-0.26	-0.30	-0.29	-0.15	-0.12	-0.12	0.01	0.04	0.02	0.02	-0.10	-	-	-	-	-	-	-	-	-
Interest Expenses	-44.4%	500,000	900,000	1,000,000	500,000	500,000	900,000	800,000	600,000	900,000	500,000	1,100,000	2,000,000	3,000,000	2,900,000	2,900,000	3,100,000	2,300,000	2,500,000	2,900,000	3,200,000	3,200,000
Income Taxes	109.1%	100,000	-1,100,000	100,000	-	2,100,000	-9,800,000	-9,100,000	-3,800,000	-5,900,000	-35,900,000	15,200,000	900,000	-10,100,000	-12,500,000	-28,500,000	-3,000,000	-15,900,000	-3,100,000	-1,700,000	-3,400,000	-3,600,000
Earnings Before Taxes	19.8%	-25,900,000	-32,300,000	-61,200,000	-116,100,000	-52,600,000	-52,100,000	-44,200,000	-17,900,000	-26,400,000	-43,500,000	39,800,000	-3,800,000	-49,600,000	-50,400,000	-43,700,000	-58,500,000	-131,100,000	-11,400,000	-22,300,000	-7,700,000	3,300,000
EBT Margin	12.6%	-0.30	-0.35	-0.38	-0.38	-0.24	-0.21	-0.20	-0.07	-0.05	-0.08	-0.09	-0.22	-	-	-	-	-	-	-	-	-
Net Income	16.7%	-26,000,000	-31,200,000	-61,300,000	-116,100,000	-54,700,000	-42,300,000	-35,100,000	-14,100,000	-20,500,000	-7,600,000	24,600,000	-4,700,000	-39,500,000	-37,900,000	-15,200,000	-55,400,000	-115,200,000	-8,300,000	-20,600,000	-4,200,000	6,900,000
Net Income Margin	13.3%	-0.30	-0.35	-0.37	-0.36	-0.21	-0.17	-0.12	-0.03	-0.01	-0.04	-0.08	-0.15	-	-	-	-	-	-	-	-	-
Free Cashflow	66.0%	-18,600,000	-54,700,000	-22,100,000	-900,000	-33,200,000	-7,300,000	-2,800,000	-49,700,000	-46,500,000	-9,500,000	-39,300,000	-4,400,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-3.1%	1,111	1,147	1,149	1,187	1,169	1,199	1,212	1,210	1,255	1,321	1,336	1,360	1,337	1,419	1,445	1,405	1,447	1,578	1,591	1,563	1,557
Current Assets	-7.4%	290	314	265	294	262	275	352	367	427	485	499	539	329	389	395	332	355	365	330	349	343
Cash Equivalents	-20.1%	106	132	76.00	103	54.00	57.00	109	104	164	257	295	118	149	117	118	164	121	81.00	90.00	93.00	85.00
Inventory	11.8%	25.00	22.00	25.00	23.00	22.00	20.00	20.00	15.00	16.00	15.00	19.00	18.00	25.00	27.00	27.00	29.00	31.00	28.00	28.00	31.00	32.00
Net PPE	-0.4%	119	119	121	112	96.00	83.00	68.00	53.00	46.00	44.00	43.00	43.00	45.00	41.00	37.00	37.00	37.00	37.00	55.00	57.00	59.00
Goodwill	-0.1%	287	287	287	287	287	287	237	238	239	239	240	240	328	329	328	328	327	408	416	417	416
Liabilities	-3.5%	351	363	466	452	334	313	295	263	305	353	367	458	462	538	535	486	480	501	517	474	476
Current Liabilities	-6.3%	146	156	209	221	143	137	129	120	166	204	203	271	149	146	134	147	113	112	115	118	109
Long Term Debt	0.5%	39.00	39.00	39.00	38.00	-	-	-	-	-	-	-	-	154	225	225	224	225	225	225	234	263
LT Debt, Non Current	-100.0%	-	39.00	39.00	38.00	-	-	-	-	-	-	-	-	-	225	-	-	-	-	-	-	-
Shareholder's Equity	-3.0%	760	783	683	735	835	886	917	947	950	968	969	902	875	881	909	918	967	1,077	1,075	1,089	1,082
Retained Earnings	-4.1%	-655	-629	-598	-537	-420	-366	-323	-288	-274	-254	-246	-271	-266	-227	-189	-173	-118	-3.30	5.00	26.00	30.00
Additional Paid-In Capital	0.2%	1,419	1,416	1,286	1,277	1,263	1,260	1,251	1,244	1,232	1,226	1,219	1,177	1,145	1,110	1,101	1,097	1,093	1,085	1,076	1,068	1,057
Accumulated Depreciation	-7.6%	111	120	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	0.7%	91.00	90.00	82.00	82.00	82.00	81.00	81.00	81.00	80.00	80.00	80.00	78.00	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-0.10	-0.10	-	-	-	-	-	0.00	-	-	-0.10
Float	-	-	-	-	1,898	-	-	-	1,465	-	-	-	2,377	-	-	-	847	-	2,030	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	66.0%	-18,600	-54,700	-22,100	-900	-33,200	-7,300	-2,800	-49,700	-46,500	-9,500	-39,300	-4,400	71,800	-14,400	-59,300	30,000	16,800	-1,900	15,800	31,500	6,600
Share Based Compensation	15.4%	12,000	10,400	11,600	11,200	7,500	8,200	9,400	10,400	10,100	8,400	10,000	8,900	9,000	6,500	8,400	1,900	7,500	7,000	8,800	8,800	9,500
Cashflow From Investing	40.8%	-7,100	-12,000	-2,500	11,800	34,600	-35,600	11,400	-12,000	-41,300	-25,900	291,000	1,100	8,200	10,900	17,100	10,350	23,200	-7,200	-7,100	4,500	-3,800
Cashflow From Financing	-107.2%	-8,800	121,900	-2,500	38,400	-4,900	-2,100	-3,600	2,500	-4,800	-1,100	-74,500	-26,500	-48,500	1,800	-3,900	950	200	1,100	-12,300	-27,800	-9,400
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	46,150

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MYGN Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Testing revenue	$ 202.2	$ 181.2
Costs and expenses:
Cost of testing revenue	64.6	59.2
Research and development expense	24.9	22.5
Selling, general, and administrative expense	140.6	151.7
Total costs and expenses	230.1	233.4
Operating loss	(27.9)	(52.2)
Other income (expense):
Interest income	0.6	0.7
Interest expense	(0.5)	(0.5)
Other	1.9	(0.6)
Total other income (expense), net	2.0	(0.4)
Loss before income tax	(25.9)	(52.6)
Income tax expense	0.1	2.1
Net loss	$ (26.0)	$ (54.7)
Net loss per share:
Basic (dollars per share)	$ (0.29)	$ (0.67)
Diluted (dollars per share)	$ (0.29)	$ (0.67)
Weighted average shares outstanding:
Basic (shares)	89.9	81.3
Diluted (shares)	89.9	81.3
Revenue from contract with customer, product and service, extensible enumeration	Testing [Member]	Testing [Member]
Cost, product and service, extensible enumeration	Testing [Member]	Testing [Member]

MYGN Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 96.9	$ 132.1
Marketable investment securities	7.4	8.8
Trade accounts receivable	118.1	114.3
Inventory	24.6	22.0
Prepaid taxes	18.4	17.0
Prepaid expenses and other current assets	24.9	19.4
Total current assets	290.3	313.6
Operating lease right-of-use assets	58.9	61.6
Property, plant, and equipment, net	118.5	119.0
Intangibles, net	340.9	349.5
Goodwill	287.0	287.4
Other assets	14.9	15.4
Total assets	1,110.5	1,146.5
Current liabilities:
Accounts payable	33.1	25.8
Accrued liabilities	99.2	113.9
Current maturities of operating lease liabilities	13.8	16.2
Total current liabilities	146.1	155.9
Unrecognized tax benefits	30.8	30.2
Long-term debt	38.7	38.5
Noncurrent operating lease liabilities	94.3	97.4
Other long-term liabilities	40.6	41.3
Total liabilities	350.5	363.3
Commitments and contingencies
Stockholders’ equity:
Common stock, 90.5 million and 89.9 million shares outstanding at March 31, 2024 and December 31, 2023, respectively	0.9	0.9
Additional paid-in capital	1,418.8	1,415.5
Accumulated other comprehensive loss	(4.2)	(3.7)
Accumulated deficit	(655.5)	(629.5)
Total stockholders' equity	760.0	783.2
Total liabilities and stockholders’ equity	$ 1,110.5	$ 1,146.5

About Myriad Genetics Inc

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. Further, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

CEO	Mr. Paul J. Diaz
WEBSITE	https://myriad.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	2600

Myriad Genetics Inc Frequently Asked Questions

What is the ticker symbol for Myriad Genetics Inc? What does MYGN stand for in stocks?

MYGN is the stock ticker symbol of Myriad Genetics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Myriad Genetics Inc (MYGN)?

As of Fri May 17 2024, market cap of Myriad Genetics Inc is 2.29 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MYGN stock?

You can check MYGN's fair value in chart for subscribers.

What is the fair value of MYGN stock?

You can check MYGN's fair value in chart for subscribers. The fair value of Myriad Genetics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Myriad Genetics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MYGN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Myriad Genetics Inc a good stock to buy?

The fair value guage provides a quick view whether MYGN is over valued or under valued. Whether Myriad Genetics Inc is cheap or expensive depends on the assumptions which impact Myriad Genetics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MYGN.

What is Myriad Genetics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, MYGN's PE ratio (Price to Earnings) is -9.76 and Price to Sales (PS) ratio is 2.96. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MYGN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Myriad Genetics Inc's stock?

In the past 10 years, Myriad Genetics Inc has provided -0.036 (multiply by 100 for percentage) rate of return.